

National Institute for Health and Care Excellence

Highly Specialised Technologies Evaluation

Setmelanotide for treating obesity caused by LEPR or POMC deficiency [ID3764]

Please note: Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

Comment 1: the draft remit

Section	Consultee/ Commentator	Comments [sic]	Action
Appropriateness	Rhythm Pharmaceuticals	Yes.	Thank you for your comment. No action required.
	GlaxoSmithKline	Yes.	Thank you for your comment. No action required.
	NHS England and Improvement	It is the opinion of NHS England that it is appropriate that NICE appraise this technology.	Thank you for your comment. No action required.
Wording	Rhythm Pharmaceuticals	Overall, the wording of the remit is satisfactory. Rhythm has provided some additional language as outlined in Comment 2.	Thank you for your comment. The wording has been amended accordingly.

Section	Consultee/ Commentator	Comments [sic]	Action
	GlaxoSmithKline	Yes.	Thank you for your comment. No action required.
	NHS England and Improvement	Yes, the remit does address the clinical issues and the cost effectiveness.	Thank you for your comment. No action required.
Timing Issues	NHS England and Improvement	As a rare disease with no other treatments expected in the near future, phase 3 clinical trial completed and new patients potentially requiring treatment this evaluation should be considered as relatively urgent.	Thank you for your comment. NICE schedules technology appraisals so that guidance to the NHS is timely. No action required.

Comment 2: the draft scope

Section	Consultee/ Commentator	Comments [sic]	Action
Background information	Rhythm Pharmaceuticals	Rhythm has applied for the brand name IMCIVREE. Rhythm prefers to use POMC deficiency obesity and LEPR deficiency obesity. It is also worth stressing that these patients are not simply hungry. They are always severely hungry , including during the night, and after eating.	Thank you for your comment. The background section has been revised accordingly.

Section	Consultee/ Commentator	Comments [sic]	Action
	NHS England and Improvement	The background is comprehensive.	Thank you for your comment. No action required.
The technology/ intervention	Rhythm Pharmaceuticals	Setmelanotide is a MC4R agonist with the potential to restore lost activity in the MC4R pathway and re-establish weight and appetite control in patients with POMC and LEPR deficiency obesity.	Thank you for your comment. The technology section has been revised accordingly.
	NHS England and Improvement	The description of the technology is accurate.	Thank you for your comment. No action required.
Population	Rhythm Pharmaceuticals	Rhythm has studied Setmelanotide in children down to 8 years of age, and clinical protocols allow for administration in children aged 6 and over.	Thank you for your comment. The population section has been revised accordingly.
	NHS England and Improvement	The population is appropriately defined. The conditions are defined by a genetic test available in the NHS, this is not mentioned in the document.	Thank you for your comment. We have added this to the background section.
Comparators	Rhythm Pharmaceuticals	There are no obvious comparators to Setmelanotide. Orlistat and methylcellulose stop the absorption of food, but these conditions are not defined by food absorption.	Thank you for your comment. The selection of comparators is intentionally kept broad

Section	Consultee/ Commentator	Comments [sic]	Action
		Bariatric surgery is not recommended for these patients as the intervention does not address the underlying severe hunger (hyperphagia).	at scoping stage. No action required.
	GlaxoSmithKline	We agree with the comparators listed.	Thank you for your comment. No action required.
	NHS England and Improvement	There are no standard treatments for these disorders and the disorders are unresponsive to standard obesity treatments.	Thank you for your comment. No action required.
Outcomes	Rhythm Pharmaceuticals	The outcomes mentioned in the Scoping document are all currently being evaluated by Rhythm.	Thank you for your comment. No action required.
	GlaxoSmithKline	Yes, we believe this is a comprehensive list	Thank you for your comment. No action required.
	NHS England and Improvement	The comparators are appropriate.	Thank you for your comment. No action required.
Equality and Diversity	NHS England and Improvement	This HST could benefit a group of patients that may often not be able to access medical care well with protected characteristics. Both conditions more common in patients who have recessive disorders resulting from consanguineous marriage.	Thank you for your comment. Where appropriate, the committee will consider any potential equality issues identified throughout the

Section	Consultee/ Commentator	Comments [sic]	Action
			evaluation and whether the recommendations make it more difficult for a particular group to access treatment. No changes made the scope.
Other considerations	NHS England and Improvement	No additional considerations.	Thank you for your comment. No action required.
Innovation	Rhythm Pharmaceuticals	Yes. Setmelanotide has demonstrated significant and sustained weight reduction in the target patient groups. Control of hunger has also been demonstrated.	Thank you for your comment. No action required.
	NHS England and Improvement	Yes, these are severe life-threatening condition without other treatments currently available.	Thank you for your comment. No action required.
Questions for consultation	GlaxoSmithKline	We consider the HST appraisal route is appropriate for this topic given the very small number of impacted people.	Thank you for your comment. No action required.
	NHS England and Improvement	Questions 1-3 these disorders are distinguished by genetic tests. Uncaptured benefits – patients with severe obesity if untreated acquire complications that are not captured in the scope. The technology may impact on other comorbidities including sleep apnoea, joint problems, severe disability.	Thank you for your comment. No action required.

